U.S. patents available from 1976 to present.
U.S. patent applications available from 2005 to present.

US Patent Application 20100069378 - SUBSTITUTED INDANYL SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS

Application 20100069378 Filed on July 25, 2007. Published on March 18, 2010

Inventors

Assignee

US Classes

514/230.5, Bicyclo ring system having the six-membered hetero ring as one of the cyclos (e.g., 1,4-benzoxazines, etc.)544/398, Chalcogen attached indirectly to the piperazine ring by nonionic bonding544/376, Bicyclo ring system having the additional hetero ring as one of the cyclos544/368, The five-membered hetero ring is one of the cyclos in a polycyclo ring system564/81, Hydrazine containing548/155, Tetramisole per se or salt thereof (including hydrogenated)544/105, Bicyclo ring system having the oxazine ring as one of the cyclos (e.g., benzoxazines, etc.)514/255.03, Carbocyclic ring bonded directly to the piperazine ring514/252.13, Additional hetero ring attached directly or indirectly to the piperazine ring by nonionic bonding514/254.02, The additional five-membered hetero ring also has chalcogen as a ring member514/602, Q contains benzene ring514/368Ring nitrogen is shared by the cyclos of the bicyclo ring system (e.g., tetramisole, etc.)

Attorney, Agent or Firm

Foreign Documents

  • 06380220.1 EP 07/31/2006

International Classes

A61K 31/18
C07D 295/12
C07D 409/12
C07D 513/04
C07C 311/21
C07D 413/12
A61K 31/4965
A61K 31/496
A61K 31/429
A61K 31/538
A61P 3/00
A61P 25/00
A61P 25/22
A61P 25/24
A61P 25/18
A61P 25/28


Claims


1. A substituted indanyl sulfonamide compound of general formula I, ##STR00050## whereinR1, R2, R3, R4, independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;R5, R6, R7 and R8, independent from one another, each represent a hydrogen atom; --NO2; --NH2; --SH; --OH; --CN; --C(=O)--H; --C(=)--R10; --OR11; --SR12; --S(=O)2--N(R14)R15, --N(R16)--S(=O)2--R17; --NH--R18; --NR19R.sup.20; F; Cl, Br; I; a linear or branched, saturated or unsaturated C1-6 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that at least one of the substituents R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 or a --N(R16)--S(=O)2--R17 radical;A represents ##STR00051## which respectively means (Ia) and (Ib) type compounds: ##STR00052## whereinn is 1, 2, 3 or 4X represents NH, O or SR23 represents NH2 or NH--NH2 or otherwise R23 together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or SR24 represents a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R9 and R9a, independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;orR9 and R9a together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s)R9b represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R10 to R22, independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1,5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C1-6 alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that when R9 and R9a form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, none of R5, R6, R7 or R8 represent --S(=O)2--N(R14)R15 or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereofoptionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

2. A substituted indanyl sulfonamide compound of general formula I, ##STR00053## whereinR1, R2, R3, R4, independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;R5, R6, R7 and R8, independent from one another, each represent a hydrogen atom; --NO2; --NH2; --SH; --OH; --CN; --C(=O)--H; --C(=O)--R10; --OR11; --SR12; --S(=O)2--N(R14)R15, --N(R16)--S(=O)2--R17; --NH--R18; --NR19R.sup.20; F; Cl, Br; I; a linear or branched, saturated or unsaturated C1-6 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that at least one of the substituents R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 or a --N(R16)--S(=O)2--R17 radical;A represents ##STR00054## which respectively means (Ia) and (Ib) type compounds: ##STR00055## whereinn is 1, 2, 3 or 4X represents NH, O or SR23 represents NH2 or NH--NH2 R24 represents a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R9 and R9a, independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;orR9 and R9a together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5alkyl)2, --S(=O)2--C.sub.1-5alkyl, --S(=O)2-phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s)R9b represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R10 to R22, independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C1-6 alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that when R9 and R9a form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, none of R5, R6, R7 or R8 represent --S(=O)2--N(R14)R15 or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereofoptionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

3. A substituted indanyl sulfonamide compound of general formula I, ##STR00056## whereinR1, R2, R3, R4, independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;R5, R6, R7 and R8, independent from one another, each represent a hydrogen atom; --NO2; --NH2; --SH; --OH; --CN; --C(=O)--H; --C(=O)--R10; --OR11; --SR12; --S(=O)2--N(R14)R15; --N(R16)--S(=O)2--R17; --NH--R18; --NR19R.sup.20; F; Cl, Br; I; a linear or branched, saturated or unsaturated C1-6 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that at least one of the substituents R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 or a --N(R16)--S(=O)2--R17 radical;A represents ##STR00057## which respectively means (Ia) and (Ib) type compounds: ##STR00058## whereinn is 1, 2, 3 or 4X represents NH, O or SR23 represents NH2 or NH--NH2 or otherwise R23 together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or SR24 represents a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R9 and R9a, independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;orR9 and R9a together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s)R9b represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R10 to R22, independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C1-6 alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that when R9 and R9a form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, R6 does not represent --S(=O)2--N(R14)R15 or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof,optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

4. A substituted indanyl sulfonamide compound of general formula I, ##STR00059## whereinR1, R2, R3, R4, independent from one another, each represent an hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;R5, R6, R7 and R8, independent from one another, each represent a hydrogen atom; --NO2; --NH2; --SH; --OH; --CN; --C(=O)--H; --C(=O)--R10; --OR11; --SR12; --S(=O)2--N(R14)R15; --N(R16)--S(=O)2--R17; --NH--R18; --NR19R.sup.20; F; Cl, Br; I; a linear or branched, saturated or unsaturated C1-6 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that at least one of the substituents R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 or a --N(R16)--S(=O)2--R17 radical;A represents ##STR00060## which respectively means (Ia) and (Ib) type compounds: ##STR00061## whereinn is 1, 2, 3 or 4X represents NH, O or SR23 represents NH2 or NH--NH2 R24 represents a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R9 and R9a, independent from one another, each represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;orR9 and R9a together with the bridging nitrogen atoms form a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF3, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)--C1-5-alkyl, --S(=O)2-phenyl and which may contain 1, 2 or 3 additional heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as a ring member(s)R9b represent a hydrogen atom; or a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3 R10 to R22, independent from one another, each represent a hydrogen atom; a linear or branched, saturated or unsaturated C1-5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; a saturated or unsaturated 3 to 8-membered cycloaliphatic radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, oxo (=O), thioxo (=S), --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --CF, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may optionally contain 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s) and which may be bonded via a linear or branched C1-6 alkylene group; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene, C2-6 alkenylene or C2-6 alkinylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s);with the condition that when R9 and R9a form a saturated, unsaturated or aromatic 3 to 9-membered heterocyclic ring optionally substituted, R6 does not represent --S(=O)2--N(R14)R15 or a pharmaceutically acceptable salt, isomer, prodrug or solvate thereof,optionally in form of one of its stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of its stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a physiologically acceptable salt thereof, or a corresponding solvate thereof.

5. An indanyl sulfonamide compound according to any of claims 1-4 wherein A represents: ##STR00062## which means (Ib) type compounds: ##STR00063##

6. An indanyl sulfonamide compound according to claim 5 where X represents NH and R23 represents NH2 or otherwise R23 together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S.

7. An indanyl sulfonamide compound according to claim 5 where X represents NH and R23 represents NH2.

8. An indanyl sulfonamide compound according to any of claims 1-4 wherein A represents ##STR00064## which means (Ia) type compounds: ##STR00065##

9. An indanyl sulfonamide compound according to claim 8 where R24 represents an hydrogen atom; R9b represents a saturated C1-5 aliphatic radical or an hydrogen atom; and R9 together with R9a represent a saturated or aromatic 3 to 9 membered heterocyclic ring or independently from one another each represent a hydrogen atom or a C1-5 aliphatic radical.

10. An indanyl sulfonamide compound according to any of claims 1-4 wherein at least one of R5, R6, R7 and R8 represents a --N(R16)--S(=O)2--R17 radical.

11. An indanyl sulfonamide compound according to any of claims 1-4 wherein at least one of R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 radical.

12. An indanyl sulfonamide compound according to claim 11 wherein at least one of R14 and R15 represents a 5- to 14-membered aryl or heteroaryl radical which may be substituted and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s).

13. An indanyl sulfonamide compound according to claim 12 wherein the 5- to 14-membered aryl or heteroaryl radical is substituted with Cl.

14. An indanyl sulphonamide derivative according to claims 1 to 4 whereinR1, R2, R3 and R4 represent an hydrogen atom or and C1-5 aliphatic radical,R5, R6, R7 and R8 represent an --S(=O)2--N(R14)R15 radical or an --N(R16)--S(=O)2--R17 radical, being R14, R15, R16 and R17 a 5- to 14-membered aryl or heteroaryl radical optionally substituted with Cl and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s)A represents ##STR00066## which respectively means (Ia) and (Ib) type compounds: ##STR00067## wherein X represents NH and R23 represents NH2 and where R24 represents an hydrogen atom, R9b represents a hydrogen atom or a linear saturated C1-5 aliphatic radical and R9 together with R9a represent a saturated or aromatic 3 to 9 membered heterocyclic ring.

15. An indanyl sulphonamide derivative according to claims 1 to 4 wherein R1, R2, R3 and R4 represent an hydrogen atom or and C1-5 aliphatic radical,R5, R6, R7 and R8 represent an --S(=O)2--N(R14)R15 radical or an --N(R16)--S(=O)2--R.sub.17 radical, being R14, R15, R16 and R17 a 5- to 14-membered aryl or heteroaryl radical optionally substituted with Cl and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulphur as ring member(s)A represents ##STR00068## which respectively means (Ia) and (Ib) type compounds: ##STR00069## wherein X represents NH and R23 represents NH2 and where R24 represents an hydrogen atom, or otherwise R23 together with X forms a saturated, unsaturated or aromatic 3- to 9-membered heterocyclic ring with up to three heteroatoms selected from N, O or S, R9b represents a hydrogen atom or a linear saturated C1-5 aliphatic radical and R9 together with R9a represent a saturated or aromatic 3 to 9 membered heterocyclic ring.

16. An indanyl sulphonamide compound of general formula I according to claim 1, selected from:[1] N-[2-methyl-3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]naphtale- ne-2-sulfonamide[2] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]naphtalene-2-sulf- onamide[3] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-5-chlo- ro-3-methylbenzo[b]thiophene-2-sulfonamide[4] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[- 2,1-b][1,3]thiazole-5-sulfonamide[5] N-[3-(piperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimidazo[2,1-b][1- ,3]thiazole-5-sulfonamide[6] N-[1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-4-yl]-6-chloroimidazo[- 2,1-b][1,3]thiazole-5-sulfonamide[7] N-[5-methoxy-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-4-yl]-5-chlo- ro-3-methylbenzo[b]thiophene-2-sulfonamide[8] 2-{6-[(2-naphthylsulfonyl)amino]-2,3-dihydro-1H-inden-1-ylidene}hydrazine- carboximidamide hydrochloride[9] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihyd- ro-1H-inden-1-ylidene)hydrazinecarboximidamide[10] 2-(4-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihyd- ro-1H-inden-1-ylidene)hydrazinecarboximidamide[11] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2-methyl-- 2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide[12] (+)-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimid- azo[2,1-b][1,3]thiazole-5-sulfonamide[13] (-)-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-6-chloroimid- azo[2,1-b][1,3]thiazole-5-sulfonamide[14] 6-chloro-N-[1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]imidazo[- 2,1b][1,3]thiazole-5-sulfonamide[15] 6-chloro-N-[1,1-dimethyl-3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-- 5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide[16] 6-chloro-N-methyl-N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl- ]imidazo[2,1-b][1,3]thiazole-5-sulfonamide[17] 6-chloro-N-(3-{[2-(dimethylamino)ethyl](methyl)amino}-2,3-dihydro-1H-inde- n-5-yl)imidazo[2,1-b][1,3]thiazole-5-sulfonamide[18] 6-chloro-N-(3-{[2-(dimethylamino)ethyl]amino}-2,3-dihydro-1H-inden-5-yl)i- midazo[2,1-b][1,3]thiazole-5-sulfonamide[19] N-[3-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden-5-yl]-4-methyl-3,4-dih- ydro-2H-1,4-benzoxazine-7-sulfonamide[20] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-3,3-dimet- hyl-2,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride[21] 2-(5-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl]amino}-2,3-dihyd- ro-1H-inden-1-ylidene) hydrazinecarboximidamide hydrochloride[22] 2-(6-{[(6-chloroimidazo[2,1-b][1,3]thiazol-5-yl)sulfonyl](methyl)amino}-2- ,3-dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride[23] 2-(6-{[(4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-yl)sulfonyl]amino}-2,3-- dihydro-1H-inden-1-ylidene)hydrazinecarboximidamide hydrochloride[24] 6-chloro-N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-2,3-dihydro-1H-inde- n-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide hydrochloride[25] 6-chloro-N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-1,1-dimethyl-2,3-di- hydro-1H-inden-5-yl]imidazo[2,1-b][1,3]thiazole-5-sulfonamide hydrochloride[26] N-[3-(4,5-dihydro-1H-imidazol-2-ylhydrazono)-2,3-dihydro-1H-inden-5-yl]-4- -methyl-3,4-dihydro-2H-1,4-benzoxazine-7-sulfonamide hydrochloride.

17. An indanyl sulphonamide compound according to any of claims 1-4 having the general formula (Ia): ##STR00070## where R1, R2, R3, R4, R5, R6, R7, R8, R9, R9a R9b, R24 have the previously mentioned meanings and n=1, 2, 3 or 4.

18. An indanyl sulphonamide compound according to any of claims 1-4 having the general formula (Ib): ##STR00071## where R1, R2, R3, R4, R5, R6, R7, R8, R23 and X have the previously mentioned meanings.

19. Process for producing indanyl sulfonamide compounds of general formula (Ia): ##STR00072## where R1, R2, R3, R4, R5, R6, R7, R8, R9, R9a R9b, R24 have the previously mentioned meanings and n=1, 2, 3 or 4 that comprises:a) reacting an indanone of general formula (II): ##STR00073## where R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning given above, with a compound of formula (III): ##STR00074## where R9, R9a and R9b have the meaning given above in the presence of a Lewis acid at a temperature between 50° C. and 70° C.,b) reduction of the material resulting from step a) with a reducing agent in a suitable solvent at reflux.

20. Process according to claim 19 wherein the Lewis acid of step a) is titanium (IV) isopropoxide.

21. Process according to claim 19 wherein the reducing step b) is carried out with a solution of sodium borohydride in ethanol.

22. Process for producing indanyl sulfonamide compounds of general formula (Ib): ##STR00075## wherein R1, R2, R3, R4, R5, R6, R7, R8, R23 and X have the previously mentioned meanings, that comprises reacting an indanone of general formula (II): ##STR00076## wherein R1, R2, R3, R4, R5, R6, R7 and R8 have the meaning given above, with a compound of formula (IV): ##STR00077## wherein R23 and X have the meaning given above, in the presence of a suitable solvent in an acid medium at reflux.

23. Process according to claim 22 wherein reaction is carried out with methanol or acetonitrile as solvent and with hydrochloric acid as acid medium.

24. An indanone of general formula (II): ##STR00078## wherein R1, R2, R3, R4, independent from one another, each represent an hydrogen atom;or a linear or branched, saturated or unsaturated C1--5 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3;R5, R6, R7 and R8, independent from one another, each represent a hydrogen atom; --NO2; --NH2; --SH; --OH; --CN; --C(=O)--H; --C(=O)--R10; --OR11; --SR12; --S(=O)2--N(R14)R15, --N(R16)--S(=O)2--R17; --NH--R18; --NR19R.sup.20; F; Cl, Br; I; a linear or branched, saturated or unsaturated C1-6 aliphatic radical which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of F, Cl, Br, --OH, --NH2, --SH, --O--CH3, --O--C2H.sub.5, --NO2, --CN, --NH--CH3 and --S--CH3; or a 5- to 14-membered aryl or heteroaryl radical, which may be substituted with 1, 2 or 3 substituent(s) independently selected from the group consisting of --CF3, C1-5-alkyl, --O--C1-5-alkyl, --S--C1-5-alkyl, --C(=O)--OH, --C(=O)--O--C1-5-alkyl, --O--C(=O)--C1-5-alkyl, F, Cl, Br, I, --CN, --OCF3, --SCF3, --OH, --SH, --NH2, --NH(C1-5-alkyl), --N(C1-5-alkyl)2, --NH--C(=O)--C1-5-alkyl, --N(C1-5-alkyl)-C(=O)--C1-5-alkyl, --NO2, --CHO, --CF2H, --CFH2, --C(=O)--NH2, --C(=O)--NH(C1-5-alkyl), --C(=O)--N(C1-5-alkyl)2, --S(=O)2--C.sub.1-5-alkyl, --S(=O)2-phenyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy and benzyl and which may be bonded via a linear or branched C1-6 alkylene group and wherein the heteroaryl radical contains 1, 2 or 3 heteroatom(s) independently selected from the group consisting of nitrogen, oxygen and sulfur as ring member(s).

25. An indanone of general formula (II) according to claim 24 wherein least one of the substituents R5, R6, R7 and R8 represents a --S(=O)2--N(R14)R15 or a --N(R16)--S(=O)2--R17 radical.

26-28. (canceled)

29. A method of treatment of a disease or disorder mediated by 5HT6 receptors comprising administering an indanyl sulphonamide compound according to any of claims 1 to 4 to a patient in need thereof.

30. The method of claim 29, wherein said administering to a patient in need thereof comprises administering for the purpose of the prophylaxis and/or treatment of disorders or diseases related to food intake, preferably for regulating appetite, for maintaining, increasing or reducing body weight, for the prophylaxis and/or treatment of obesity, bulimia, anorexia, cachexia or diabetes type II, or for the prophylaxis and/or treatment of irritable bowel syndrome; disorders of the central nervous system, anxiety; panic attacks; depression; bipolar disorders; cognitive disorders; memory disorders; senile dementia; psychosis; schizophrenia; neurodegenerative disorders preferably selected between Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; or hyperactivity disorders, preferably attention deficit/hyperactivity disorder, or for improving cognitive capacity.

31. Pharmaceutical composition comprising a compound according to any of claims 1-4 and at least a pharmaceutically acceptable additive.

PatentsPlus Images
Enhanced PDF formats
loading...
PatentsPlus: add to cart
PatentsPlus: add to cartSearch-enhanced full patent PDF image
$9.95more info
 
Sign InRegister
Username  
Password   
forgot password?